DR. RIMAS VINCAS LUKAS M.D. NPI 1396954269

NPI Details

DR. Rimas Vincas Lukas, M.D. is a hematology and oncology internal medicine in Chicago, IL with 24 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Rimas Vincas Lukas, M.D. NPI is 1396954269. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: RUSH MEDICAL COLLEGE OF RUSH UNIVERSITY
Graduation Year:2002

The provider's business location address is:

675 N SAINT CLAIR ST STE 20-100
CHICAGO, IL
ZIP 60611-970
Phone: (312) 695-4360
Fax: (312) 695-1435

The NPI 1396954269 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, carfilzomib, 1 mg (HCPCS:J9047)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, pemetrexed, not otherwise specified, 10 mg (HCPCS:J9305)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, bortezomib, not otherwise specified, 0.1 mg (HCPCS:J9044)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Unclassified drugs (HCPCS:J3490)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Hospital discharge day management, 30 minutes or less (HCPCS:99238)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0221)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)

The enumeration date for this NPI number is 5/21/2007 and was last updated on 11/8/2021.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: